Evidence map›Paper›PMID 31013756›Full record

ArticleGenes2019

Tracking Biodistribution of Myeloid-Derived Cells in Murine Models of Breast Cancer.

Jun Li, Junhua Mai, Louis Hinkle, Daniel Lin, Jingxin Zhang, Xiaoling Liu, Maricela R Ramirez, Youli Zu, Ganesh L Lokesh, David E Volk and 1 more

Abstract read
In one paragraph

Article in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jun LiDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. jli6@houstonmethodist.org.
Junhua MaiDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. jmai@houstonmethodist.org.ORCID 0000-0001-8374-4352
Louis HinkleDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. lehinkle@houstonmethodist.org.
Daniel LinDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. dlin@houstonmethodist.org.
Jingxin ZhangDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. jzhang4@houstonmethodist.org.
Xiaoling LiuDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. liuxiaoling97@aliyun.com.
Maricela R RamirezDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. MReyes2@houstonmethodist.org.
Youli ZuDepartment of Pathology and Genomic Medicine, Houston, TX 77030, USA. yzu@houstonmethodist.org.
Ganesh L LokeshInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. loks154@yahoo.com.
David E VolkInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. David.Volk@uth.tmc.edu.ORCID 0000-0002-4372-6915
Haifa ShenDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA. hshen@houstonmethodist.org.

Funding

Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, RONGFU · 2016 to 2020
$9.3M
Mechanism of Intratumoral Transport of Particulate DrugsR01CA222959 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, SHU-HSIA, LIU, XUEWU · 2018 to 2023
$2.3M
Tumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA193880NCI NIH HHS R01 CA222959NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

A growing tumor is constantly secreting inflammatory chemokines and cytokines that induce release of immature myeloid cells, including myeloid-derived suppressor cells (MDSCs) and macrophages, from the bone marrow. These cells not only promote tumor growth, but also prepare distant organs for tumor metastasis. On the other hand, the myeloid-derived cells also have phagocytic potential, and can serve as vehicles for drug delivery. We have previously identified thioaptamers that bind a subset of MDSCs with high affinity and specificity. In the current study, we applied one of the thioaptamers as a probe to track myeloid cell distribution in the bone, liver, spleen and tumor in multiple murine models of breast cancer including the 4T1 syngeneic model and MDA-MB-231 and SUM159 xenograft models. Information generated from this study will facilitate further understanding of tumor growth and metastasis, and predict biodistribution patterns of cell-mediated drug delivery.

Indexed as

AnimalsAptamers, NucleotideBone and BonesBreast NeoplasmsCell Line, TumorCell TrackingFemaleGranulocytesHumansLiverMacrophagesMiceMyeloid-Derived Suppressor CellsNeoplasm TransplantationSpleenTissue DistributionAptamers, Nucleotidebiodistributionbreast cancermyeloid-derived suppressor cellthioaptamer

Identifiers

PMID31013756
PMCPMC6523772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.